8-K

NY false 0001802768 0001802768 2026-06-04 2026-06-04
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 

FORM 8-K
 
 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2026
 
 

Royalty Pharma plc
(Exact Name of Registrant as Specified in its Charter)
 
 

 

England and Wales
 
001-39329
 
98-1535773

(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S.
Identification No.)

 

110 East 59 th Street
New York , New York

 
10022

(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code: (212) 883-0200
Not Applicable
(Former name or former address, if changed since last report)
 
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
 

Title of each class

 
Trading
symbol(s)

 
Name of each exchange
on which registered

Class A Ordinary Shares, par value $0.0001 per share
 
RPRX
 
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 

Item 5.07.
Submission of Matters to a Vote of Security Holders.

On June 4, 2026, Royalty Pharma plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on 10 proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 10, 2026 (the “Proxy Statement”). There were 508,180,103 shares of the Company’s Class A ordinary shares and Class B ordinary shares, voting as a single class, present or represented by proxy at the Annual Meeting, which represented 88.08% of the combined voting power of the Class A ordinary shares and Class B ordinary shares entitled to vote at the Annual Meeting, and which constituted a quorum for the transaction of business. Holders of the Company’s Class A ordinary shares and Class B ordinary shares were entitled to one vote for each share held as of the record date described in the Proxy Statement. The Company’s inspector of election certified the following vote tabulations:
Proposal 1. To elect nine directors, each by separate ordinary resolutions, to the Company’s Board of Directors to serve until the 2027 Annual General Meeting of Shareholders:
 

Nominee
  
For
  
Against
  
Abstain
  
Broker Non-Votes

Pablo Legorreta

  
458,242,360
  
29,448,236
  
168,578
  
20,320,929

Ted Love, M.D.

  
464,556,053
  
23,135,217
  
167,904
  
20,320,929

Bonnie Bassler, Ph.D.

  
486,078,663
  
1,615,471
  
165,040
  
20,320,929

Vlad Coric, M.D.

  
433,218,530
  
54,472,087
  
168,557
  
20,320,929

Catherine Engelbert

  
485,200,369
  
2,492,809
  
165,996
  
20,320,929

Carole Ho, M.D.

  
487,136,029
  
557,922
  
165,223
  
20,320,929

David Hodgson

  
479,933,527
  
7,733,381
  
192,266
  
20,320,929

Gregory Norden

  
481,576,664
  
6,090,949
  
191,561
  
20,320,929

Elizabeth Weatherman

  
487,564,658
  
128,998
  
165,518
  
20,320,929

Proposal 2. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers:
 

For
  
Against
  
Abstain
  
Broker Non-Votes

476,044,602
  
11,067,486
  
747,086
  
20,320,929

Proposal 3. To ratify the appointment of Ernst & Young LLP, as the Company’s independent registered public accounting firm:
 

For
  
Against
  
 
  
Abstain

506,307,829
  
832,217
  

  
1,040,057

There were no broker non-votes on this proposal.
Proposal 4. To approve receipt of the Company’s U.K. statutory accounts together with the Company’s U.K. statutory reports, including the directors’ report, the strategic report, the directors’ remuneration report and the auditors’ report for the fiscal year ended December  31, 2025 (“U.K. Annual Report and Accounts”) :
 

For
  
Against
  
Abstain
  
Broker Non-Votes

487,151,335
  
98,040
  
609,799
  
20,320,929

Proposal 5. To approve, on a non-binding advisory basis, the Company’s U.K. directors’ remuneration report in the U.K. Annual Report and Accounts:
 

For
  
Against
  
Abstain
  
Broker Non-Votes

478,165,378
  
8,935,552
  
758,244
  
20,320,929

 

Proposal 6. To re-appoint Ernst & Young as the Company’s U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders:
 

For
  
Against
  
 
  
Abstain

506,752,136
  
384,952
  

  
1,043,015

There were no broker non-votes on this proposal.
Proposal 7. To authorize the Board of Directors to determine the remuneration of the Company’s U.K. statutory auditor:
 

For
  
Against
  
Abstain
  
Broker Non-Votes

487,092,662
  
575,800
  
190,712
  
20,320,929

Proposal 8. To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A ordinary shares:
 

For
  
Against
  
Abstain
  
Broker Non-Votes

474,475,427
  
12,499,628
  
884,119
  
20,320,929

Proposal 9. To authorize the Board of Directors to allot shares:
 

For
  
Against
  
Abstain
  
Broker Non-Votes

469,111,384
  
18,568,396
  
179,394
  
20,320,929

Proposal 10. To authorize the Board of Directors to allot shares without rights of pre-emption:
 

For
  
Against
  
Abstain
  
Broker Non-Votes

445,653,078
  
42,016,406
  
189,690
  
20,320,929

 

SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 

 

 
ROYALTY PHARMA PLC

Date: June 4, 2026
 

 
By:
 
/s/ Arthur McGivern

 

 

 
Arthur McGivern

 

 

 
EVP, General Counsel & Investments